Orgenesis Inc. (ORGS)

NASDAQ: ORGS · IEX Real-Time Price · USD
2.31 0.00 (0.00%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap56.08M
Revenue (ttm)30.91M
Net Income (ttm)64.65M
Shares Out24.28M
EPS (ttm)-2.44
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume122,105
Open2.30
Previous Close2.31
Day's Range2.12 - 2.35
52-Week Range2.12 - 8.30
Beta1.18
AnalystsStrong Buy
Price Target9.00 (+289.6%)
Earnings DateNov 4, 2021

About ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at t...

IndustryBiotechnology
Founded2008
CEOVered Caplan
Employees111
Stock ExchangeNASDAQ
Ticker SymbolORGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for Orgenesis stock is "Strong Buy" and the 12-month stock price forecast is 9.00.

Price Target
$9.00
(289.61% upside)
Analyst Consensus: Strong Buy

News

Orgenesis-Theracell Joint Venture Secures €32M Grant From Greek Government

Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance.

1 month ago - Benzinga

Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

Orgenesis to host conference call today at 8:30AM ET Orgenesis to host conference call today at 8:30AM ET

2 months ago - GlobeNewsWire

Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

2 months ago - GlobeNewsWire

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Goal to accelerate development, QC testing and manufacturing  of Orgenesis' cell and gene therapy platform

4 months ago - GlobeNewsWire

Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

GERMANTOWN, MD / ACCESSWIRE / August 12, 2021 / Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be pr...

5 months ago - Accesswire

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

5 months ago - GlobeNewsWire

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator...

Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgery Investigator-initiated, rand...

7 months ago - GlobeNewsWire

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

7 months ago - GlobeNewsWire

Orgenesis First Quarter 2021 Revenue Increases 400% to $9.4 Million Reflecting Initial Success of POCare Platform

Achieves operating profit for the first quarter of 2021

8 months ago - GlobeNewsWire

Orgenesis Schedules First Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

8 months ago - GlobeNewsWire

Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of...

GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

9 months ago - GlobeNewsWire

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of ...

GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

10 months ago - GlobeNewsWire

Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call

GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

10 months ago - GlobeNewsWire

Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform

Reports rapid advancement of therapeutic pipeline

1 year ago - GlobeNewsWire

Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders

GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

1 year ago - GlobeNewsWire

Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology ...

Icellator® commercially available for lipotransfer in first two countries with more approvals expected Icellator® commercially available for lipotransfer in first two countries with more approvals expected

1 year ago - GlobeNewsWire

Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies

Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®,  a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis

1 year ago - GlobeNewsWire

Orgenesis CEO to Participate in Webinar Panel on “New Approaches to COVID-19” on Thursday, September 10th

GERMANTOWN, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene ther...

1 year ago - GlobeNewsWire

Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase f...

GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene thera...

1 year ago - GlobeNewsWire

Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

Provides update on COVID-19 therapeutic programs

1 year ago - GlobeNewsWire

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary P...

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and ...

1 year ago - GlobeNewsWire

Orgenesis Added to Russell 3000® Index

GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...

1 year ago - GlobeNewsWire

Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19

GERMANTOWN, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...

1 year ago - GlobeNewsWire

Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Vir...

GERMANTOWN, Md., June 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and ...

1 year ago - GlobeNewsWire